2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Ruben A. Mesa, MD, discusses the rationale for the phase 3 MOMENTUM study in myelofibrosis.
Ruben A. Mesa, MD, executive director, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, discusses the rationale for the phase 3 MOMENTUM study (NCT04173494) in myelofibrosis.
MOMENTUM examined the efficacy of momelotinib vs danazol in patients with primary myelofibrosis, post–polycythemia vera myelofibrosis, or post–essential thrombocytopenia myelofibrosis with symptomatic disease and anemia.
This study was meant to enhance the understanding of the impact of momelotinib in this patient population, Mesa says. The prior phase 3 Simplify 1 trial (NCT01969838) had examined momelotinib in the frontline setting vs ruxolitinib (Jakafi).
MOMENTUM aimed to target patients who had significant anemia and symptoms, and who had previously failed on ruxolitinib, Mesa adds. The primary goal of MOMENTUM was to improve symptoms, with secondary end points of improved splenic response and transfusion independence, against the current standard of care, danazol.
On the trial, 195 patients were randomized 2:1 between momelotinib once daily at standard 200 mg vs danazol, Mesa continues. The placebo-controlled study allowed subsequent crossover for patients to receive momelotinib, Mesa concludes.